Heron Therapeutics is trading 15.08% down at $0.26, despite broad U.S. markets moving higher on September 21, 2026; no new company-specific announcement clearly explains the decline.
- Investors remain aware of earlier CINVANTI patent uncertainty.
- Heron withdrew 2026 guidance, and strategic-review concerns remain prior developments rather than confirmed same-day catalysts.
- The stock is underperforming the broader risk-on market.